ADRC Home >> About the ADRC >> ADRC Faculty >> Murray Raskind

Murray Raskind, M.D.

Position: Professor

Qualifications:

• B.A., Brown University, Providence, RI, History, 1964
• M.D., Columbia Univ Coll of Phys. & Surgs., NY, NY, Medicine, 1968
• Resident, Columbia Univ Coll of Phys. & Surgs., NY, Internal Medicine, 1968-70
• Resident, University of Washington, Seattle, WA, Psychiatry, 1970-73

Past Positions:

• 1998-present, Director, Alzheimer's Disease Research Center (ADRC), University of Washington
• 1997-present, Director, Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System
• 1996-present, Director, Mental Health Service, VA Puget Sound Health Care System
• 1987-1998, Associate Director, Alzheimer's Disease Research Center (ADRC), University of Washington
• 1976-1987, Director, Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System
• 1985-present, Professor and Vice-Chairman, Department of Psychiatry and Behavioral Sciences, University of Washington
• 1979-1985, Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Washington
• 1975-1979, Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of Washington
• 1973-1976, Instructor, Department of Psychiatry and Behavioral Sciences, University of Washington
• 1972-1973, Chief Resident, Department of Psychiatry and Behavioral Sciences, University of Washington

Honors and Awards:

• 1990-present, Medical and Scientific Advisory Council, Alzheimer's Association, Vice-Chairperson (1997-present)
• 1988-1992, Neuroscience, Behavior and Sociology of Aging Review Committee "A", National Institute on Aging, Chairperson 1991-1992
• 1986-1992, National Scientific Advisory Council, American Federation of Aging Research
• 1986-1990, Board of Directors, American Geriatrics Society
• 1985, Outstanding Teacher Award, University of Washington School of Medicine

Selected Publications:

• Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, Raskind M, Peskind E, Newhouse P, Sack D, DeSouza E, Sadowsky C, Roberts E, and the DHEA-Alzheimer's Disease Collaborative Research Group. DHEA treatment of Alzheimer's disease. A randomized, double-blind, placebo-controlled study. Neurology 60:1071-1076, 2003.
• Leverenz JB, Agustin C, Tsuang D, Peskind ER, Edland S, Nochlin D, Bowen J, McCormick W, Teri L, Raskind MA, Kukull W, Larson EB. Clinical and neuropathological characteristics of hippocampal sclerosis: a community based study. Arch Neurol 59:1099-1106, 2002.
• Teri L, Logsdon RG, Peskind E, Raskind M, et al. Treatment of agitation in Alzheimer's disease: an investigation of Haloperidol, Trazodone, and behavior management techniques. Research and Practice in Alzheimer's Disease 6:232-236, 2002.
• Raskind MA, Barnes RF. Alzheimer's disease: treatment of noncognitive behavioral abnormalities. In: Davis K, Charney D, Coyle J, Nemeroff C (eds.), Psychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology, Lippincott Williams and Wilkins, New York, pp. 1253-1265, 2002.
• Raskind MA, Wilkinson CW, Peskind ER. Aging and Alzheimer's disease. In: Hormones, Brain and Behavior, Vol. 5, Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds.), Academic Press: San Diego, CA, pp. 637-664, 2002.
• Wilkinson CW, Petrie EC, Murray SR, Colasurdo EA, Raskind MA, Peskind ER. Human glucocorticoid feedback inhibition is reduced in older individuals: evening study. J Clin Endocrinol Metab 86:545-550, 2001.
• Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology 56:1094-1098, 2001.
• Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, Plymate SR. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 57:605-612, 2001.
• Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 39:409-413, 2001.
• Raskind MA, Peskind ER. Alzheimer's disease and related disorders. Medical Clinics of North America 85:803-817, 2001.
• Leverenz JB, Miller MA, Dobie DJ, Peskind ER, Raskind MA. Increased alpha 2-adrenergic receptor bindings in locus ceruleus projection areas in dementia with Lewy bodies. Neurobiol Aging 22:555-561, 2001.
• Raskind MA, Peskind ER. Treatment of noncognitive symptoms in Alzheimer's disease and other dementias. In: AF Shatzberg and CB Nemeroff (eds.), Essentials of Clinical Psychopharmacology. Washington DC, American Psychiatric Press, pp. 447-457, 2001.
• Petrie EC, Peskind ER, Dobie DJ, Veith RC, Raskind MA. Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging. Psychoneuroendocrinology 26:147-164, 2001.
• Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB. Clinico-neuropathologic correlation of Alzheimer's disease in a community-based case series. JAGS 47:564-569, 1999.
• Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg G. Tau is a candidate gene for chromosome 17 frontotemporal dementia? Ann Neurol 43:815-825, 1998.
• Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte Jr, D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: a relationship to severity of dementia and Apolipoprotein E genotype. Neurology 50(1):164-168, 1998.
• Raskind MA, Sadowsky CH, Sigmund WR, Gracon SL, Beitler PJ, Auster SB. Effect of tacrine on language, praxis and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol 54:836-840, 1997.
• Tsuang D, Raskind MA, Leverenz J, Peskind ER, Schellenberg GD, Bird TD. The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. Biol Psychiatry 41:191-195, 1997.
• Wilkinson CW, Peskind ER, Raskind MA. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology 65:79-90, 1997.
• Tsuang D, Raskind MA, Leverenz J, Peskind ER, Schellenberg GD, Bird TD. The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. Biol Psychiatry 41:191-195, 1997.
• Tsuang D, Kukull W, Sheppard L, Barnhart RL, Peskind E, Edland SD, Schellenberg G, Raskind M, Larson EB. Impact of sample selection on APOEe4 allele frequency: a comparison of two Alzheimer's disease samples. JAGS 44:704-707, 1996.
• Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal L, Dobie DJ, Wilkinson CW. Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender. Biol Psychiatry 40:61-68, 1996.
• Tsuang D, Kukull W, Sheppard L, Barnhart RL, Peskind E, Edland SD, Schellenberg G, Raskind M, Larson EB. Impact of sample selection on APOE e4 allele frequency: a comparison of two Alzheimer's disease samples. JAGS 44:704-707, 1996.
• Peskind ER, Wingerson D, Pascualy M, Thal L, Veith RC, Dorsa DM, Bodenheimer S, Raskind MA. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Biol Psychiatry 38:532-538, 1995.
• Walker SA, Borson S, Katon W, Peskind E, Corbin S, Cashman J, McLaughlin M, Raskind M. Differential clinical characteristics of older Black and White nursing home residents. Am J Geri Psychiatry 3:229-238, 1995.
• Peskind ER, Wingerson D, Murray S, Pascualy M, Dobie DJ, Le Corre P, Le Verge R, Veith RC, Raskind MA. Enhanced cerebrospinal fluid norepinephrine and behavioral responses to yohimbine in Alzheimer's disease and normal aging. Arch Gen Psychiatry 52:774-782, 1995.
• Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ, Veith RC, Dorsa DM, Murray S, Sikkema C, Galt SA, Wilkinson CW. Enhanced hypothalamic pituitary adrenocortical axis responses to physostigmine in normal aging. J Gerontology 50A:M114-M120, 1995.